Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix

7. marts 2012 opdateret af: British Columbia Cancer Agency

Genomics Approach to Id Novel Targets & Markers for Early Detection And Intervention In Cancer (Cervical)

RATIONALE: Studying the genes expressed in samples of tissue from patients with abnormal cells may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial is identifying biomarkers for early detection of cancer in women with cervical dysplasia or carcinoma in situ of the cervix.

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

OBJECTIVES:

Primary

  • To identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer.
  • To identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design.

Secondary

  • To complete genome scans at high density and analysis of gene and protein expression to identify recurrent genetic and protein changes in cancer.
  • To confirm changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes.

OUTLINE: Patients undergo biopsy of cervical tissue followed by loop electrocautery excision procedure (LEEP) (removing all of the tissue surrounding and under the area biopsied). RNA, DNA, and protein is extracted from the cells to provide material for the construction of libraries for Serial Analysis of Gene Expression (SAGE analysis); for hybridization against Bacterial Artificial Chromosome Comparative Genome Hybridization arrays (BAC CGH arrays); and for analysis using protein chip arrays and proteomics. Resulting data from coded samples provide gene expression and protein profiles. The coded molecular datasets are linked, analyzed, and compared using a variety of statistical software to identify putative genes, gene alterations, and proteins of interest. Some samples may be banked for future studies.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

80

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

19 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

All patients attending Vancouver General Hospital and referred to colposcopy for loop electrocautery excision procedure (LEEP).

Beskrivelse

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed premalignant lesion, dysplasia, or carcinoma in situ of the cervix
  • Clinically documented disease
  • Attending Vancouver General Hospital and referred to colposcopy for loop electrocautery excision procedure (LEEP)

PATIENT CHARACTERISTICS:

  • Not pregnant
  • No lack of informed consent due to language difficulty, physical and mental condition

PRIOR CONCURRENT THERAPY:

  • No prior operation for removal of the cervix
  • Concurrent therapy allowed

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer
Tidsramme: Done at the completion of the study.
Done at the completion of the study.
Identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design
Tidsramme: Done at the completion of the study.
Done at the completion of the study.
Completion of genome scans at high density and analysis of gene and protein expressions to identify recurrent genetic and protein changes in cancer
Tidsramme: Done at the completion of the study.
Done at the completion of the study.
Changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes
Tidsramme: Done at the completion of the study.
Done at the completion of the study.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studiestol: Sylvia Lam, British Columbia Cancer Agency

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. december 2004

Primær færdiggørelse (Faktiske)

1. april 2009

Studieafslutning (Faktiske)

1. maj 2011

Datoer for studieregistrering

Først indsendt

25. januar 2008

Først indsendt, der opfyldte QC-kriterier

25. januar 2008

Først opslået (Skøn)

28. januar 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

9. marts 2012

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. marts 2012

Sidst verificeret

1. marts 2012

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Livmoderhalskræft

3
Abonner